Alethio Therapeutics Ltd, a biotech developing therapies for a group of blood cancers called MPNs, has appointed Rohit Batta as chief executive officer and Mike Grey as chair of the board. The appointments support the company’s discovery and development strategy as it advances two antibody-drug conjugate programmes. Dr Batta joins Alethio Therapeutics from Ferring Ventures, where he was managing director, and previously was chief medical officer at Vicore Pharma. Mr Grey has founded and grown several biotechnology companies and is currently Chair/Executive Chair of Mirum Pharmaceuticals, Sorriso Pharmaceuticals, Spruce Biosciences, Plexium and Theolytics. Alethio Therapeutics was founded by Professors Adam Mead and Beth Psaila from the University of Oxford, UK and is based near Oxford.
Alethio Therapeutics announced the appointments on 30 October 2025.
Copyright 2025 Evernow Publishing Ltd.